At Revivebio, our management team consists of passionate, forward-thinking and highly skilled leaders focused on driving innovation and business growth. Leveraging cutting-edge technology and the team’s extensive experience in the medical, health supplement, and skincare markets, we develop high-quality, scientifically validated products that meet diverse and evolving consumer needs.
Our team members possess deep expertise in market strategy, product development, and operations, continuously leading industry trends and fostering innovation. We uphold integrity, creativity, and excellence as our core values, actively expanding our product portfolio, enhancing corporate influence, and building long-term trust with customers and partners.
Our vision is to create meaningful impacts on health and well-being through superior products and the highest industry standards, establishing ourselves as a global leader in the health and wellness market.
Dr. Hsin Chih Lai serves as the General Manager of REVIVEBIO since 2023. He holds a Ph.D. in Pathology from the University of Cambridge (1994), a Master’s in Microbiology and Immunology from National Yang-Ming Medical College (1988), and a Bachelor’s degree in Medical Technology from National Taiwan University (1986).
Dr. Lai is a distinguished academic and industry leader with extensive experience in microbiology, immunology and biotechnology. He is an adjunct professor at National Taiwan University’s Department of Medical Laboratory Science and Biotechnology and holds multiple editorial roles in international scientific journals such as Frontiers in Pharmacology and PLOS ONE. He also serves as a board member of the Taiwan Microbiome Alliance.
Throughout his career, Dr. Lai has held key academic positions, including director roles in microbiome research centers and research institutes in both Taiwan and China. His research focuses on the interplay between gut microbiota and host immunity, discovery of novel probiotics and bioactive compounds, as well as the development of biosensors for infectious diseases, and to date, Dr. Lai has published or co-published over 137 SCI papers.